Evidence map›Paper›PMID 39398923›Full record

ArticleInternational cancer conference journal2024

A case of gastritis caused by immune checkpoint inhibitor treated with infliximab.

Shizu Itsukage, Noriko Kume, Aki Tajima, Takashi Okazaki, Koji Tsuta, Hideaki Tanizaki

Abstract read
In one paragraph

Article in International cancer conference journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Shizu ItsukageDepartment of Dermatology, Kansai Medical University Hospital, 2-5-1 Shinmachi, Hirakata City, Osaka Japan.ORCID 0000-0002-9535-5706
Noriko KumeDepartment of Dermatology, Kansai Medical University Hospital, 2-5-1 Shinmachi, Hirakata City, Osaka Japan.
Aki TajimaDepartment of Dermatology, Kansai Medical University Hospital, 2-5-1 Shinmachi, Hirakata City, Osaka Japan.
Takashi OkazakiThird Department of Internal Medicine, Kansai Medical University Hospital, Hirakata City, Japan.
Koji TsutaDepartment of Pathology, Kansai Medical University Hospital, Hirakata City, Japan.
Hideaki TanizakiDepartment of Dermatology, Kansai Medical University Hospital, 2-5-1 Shinmachi, Hirakata City, Osaka Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune checkpoint inhibitors (ICIs) can cause immune-related adverse events (irAEs) in various organs. Herein, we present a rare case involving a patient with immunotherapy-related gastritis who developed refractory vomiting and anorexia after treatment with nivolumab for cutaneous malignant melanoma. The patient was treated with oral corticosteroids, but the efficacy was limited. The symptoms improved markedly after treatment with infliximab. With the increasing use of ICIs, the number of reports of gastritis due to irAEs has also increased. Health care providers treating malignancies should be aware of this side effect and know how to diagnose and treat it.

Indexed as

GastritisImmune checkpoint inhibitorsImmune-related adverse eventsInfliximabNivolumab

Identifiers

PMID39398923
PMCPMC11464928

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.